IRMD Earnings Date: Feb 9, 2027 (Estimated) — IRadimed Corporation
NASDAQ · Healthcare · Medical Devices
Updated
When is IRMD's next earnings date?
IRadimed Corporation (IRMD) is expected to report Q4 2026 earnings on Tuesday, February 9, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.62 on revenue of $26.2M.
How did IRMD do in its last earnings report?
In its most recent report on Oct 30, 2026 (Q3 2026), IRadimed Corporation posted EPS of $0.55 versus the $0.55 estimate, an in-line result. Revenue was $24.2M against a $23.5M estimate.
How much does IRMD stock move after earnings?
IRMD beat EPS estimates in 6 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 8.1% (up or down) in the day after earnings.
About IRadimed Corporation
IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
🤖 AI Earnings Analysis
iRadimed’s MRI-compatible device business posted a solid, revenue-led quarter: sales rose 14% to $24M, topping estimates, while EPS of $0.55 matched consensus. Full-year guidance of $91M–$96M revenue supports continued growth, though the unusually large reported growth rates appear unreliable.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | Q3 2026 | 0.55 | 0.55 | +0.00% | $24.2M | ➖ Inline | — | — | — |
| 2026-07-31 | Q2 2026 | 0.44 | 0.46 | +4.55% | $20.5M | ✅ Beat | -4.57% | -4.20% | -8.34% |
| 2026-05-01 | Q1 2026 | 0.44 | 0.49 | +11.36% | $22.0M | ✅ Beat | +4.44% | +3.95% | +10.57% |
| 2026-02-10 | Q4 2025 | 0.46 | 0.54 | +17.39% | $22.7M | ✅ Beat | +9.58% | +4.86% | +5.25% |
| 2025-11-03 | Q3 2025 | 0.45 | 0.47 | +4.44% | $21.2M | ✅ Beat | +9.50% | +9.79% | +20.10% |
| 2025-08-01 | Q2 2025 | 0.43 | 0.49 | +13.95% | $20.4M | ✅ Beat | +13.41% | +18.22% | +24.46% |
| 2025-02-13 | Q4 2024 | 0.44 | 0.44 | +0.00% | $19.4M | ➖ Inline | -8.40% | -5.53% | -13.02% |
| 2024-10-31 | Q3 2024 | 0.38 | 0.43 | +13.16% | $18.3M | ✅ Beat | -6.93% | +6.16% | +2.15% |
Showing last 8 quarters.